drugset / Trial / NCT00004488

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

NCT00004488 ↗

Phase 2 Completed 82 enrolled Children's Hospital Medical Center, Cincinnati
RandomizedSingle-groupDouble-blindTreatment

Summary

OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.

Timeline

Start
1998-10
Primary completion
—
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule — Oral
Background Calcium carbonate Other / unclassified — Oral
Background Cholecalciferol Other / unclassified — Oral